Overview

Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

Status:
Completed

Trial end date:
2021-11-28

Target enrollment:

Participant gender:

Summary

This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers. we advocate comparing the clinical efficacy rather than simple bioequivalence comparison.

Phase:

Phase 3

Details

Lead Sponsor:

Cairo University

Treatments:

Ticagrelor